Ajanta Pharma Results Earnings Call for Q4FY23
Conference Call with Ajanta Pharma Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.05-05-2023
05-05-2023
AJANTA PHARMA LTD. - 532331 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements), 2015
Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of Related Party Transactions in the prescribed format for the half year ended 31st March 2023.05-05-2023
Ajanta Pharma Q4 earnings: Net profit down 19% in Q4, R&D expenses up 7%
Ajanta Pharma, a mid-size firm, closed today's trading session with a market worth of 16,201.44 Cr.05-05-2023
AJANTA PHARMA LTD. - 532331 - Allotment Of Shares Under SBIP 2019 And Grant Of Options.
This is to inform that the Nomination & Remuneration Committee of the Board has at its meeting held today: a. Granted options under Ajanta Pharma Share Based Incentive Plan 2019 and b. Allotted 1,000 fully paid-up equity shares of Rs. 2/- each issued upon exercise of options. In view of the above, the paid-up capital of the Company stands increased to Rs. 25,18,31,310 consisting of 12,59,15,655 equity shares of Rs. 2/- each. Company will be making application for listing of these shares in due course.05-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Ajanta Pharma Ltd.
Ajanta Pharma announced Q4FY23 & FY23 results: Q4FY23: Revenue from operations at Rs 882 crore against Rs 870 crore; up 1%. EBITDA at Rs 149 crore against Rs 207 crore; EBITDA at 17% of revenue from operations. Profit after tax at Rs 122 crore against Rs 151 crore; PAT at 14% of revenue from operations. FY23: Revenue from operations at Rs 3,743 crore against Rs 3,341 crore, up 12%. EBITDA at Rs 783 crore against Rs 929 crore; EBITDA at 21% of revenue from operations. Profit after tax at Rs 588 crore against Rs 713 crore, PAT at 16% of revenue from operations. Result PDF05-05-2023
AJANTA PHARMA LTD. - 532331 - Audited (Consolidated & Standalone) Financial Results For The Quarter And Year Ended 31St March 2023
Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith following: 1. Press Release; 2. Audited Consolidated Financial Results for the quarter and year ended 31st March 2023 along with statement of Assets & Liabilities, Cashflow statement and Auditors' report with unmodified opinion; 3. Audited Standalone Financial Results for the quarter and year ended 31st March 2023 along with statement of Assets & Liabilities, Cashflow statement and Auditors' report with unmodified opinion; 4. Investor presentation.05-05-2023
AJANTA PHARMA LTD. - 532331 - Audited (Consolidated & Standalone) Financial Results For The Quarter And Year Ended 31St March 2023
Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith following: 1. Press Release; 2. Audited Consolidated Financial Results for the quarter and year ended 31st March 2023 along with statement of Assets & Liabilities, Cashflow statement and Auditors' report with unmodified opinion; 3. Audited Standalone Financial Results for the quarter and year ended 31st March 2023 along with statement of Assets & Liabilities, Cashflow statement and Auditors' report with unmodified opinion; 4. Investor presentation.05-05-2023
AJANTA PHARMA LTD. - 532331 - Board Meeting Outcome for Outcome Of Board Meeting
We hereby inform that at the Board meeting held on Friday, 5th May 2023, Board has inter-alia approved and taken on record the Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2023. Board has also approved amendment in the object clause of Memorandum of Association (MOA) to align the same with regulatory requirements. There is no change in the principal business of the Company. This amendment is subject to approval of the shareholders at the ensuing Annual General Meeting.05-05-2023
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 5th May 2023, post Board meeting.27-04-2023